ARIC Manuscript Proposal #2402

PC Reviewed: 8/12/14  Status: A  Priority: 2
SC Reviewed: _________  Status: _____  Priority: ____

1.a. Full Title: The Prevalence of CHF stages in African Americans and their relation to mortality and incident CV events

   b. Abbreviated Title: Prevalence of CHF stages in AA and relation of stage to mortality and incident CV events.

2. Writing Group:

   Writing group members:

<table>
<thead>
<tr>
<th>Name</th>
<th>Contact Information</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solomon Musani</td>
<td><a href="mailto:smusani@umc.edu">smusani@umc.edu</a></td>
<td>Statistics/co-investigator</td>
</tr>
<tr>
<td>Vanessa Xanthakis</td>
<td><a href="mailto:vanessax@bu.edu">vanessax@bu.edu</a></td>
<td>Statistics/co-investigator</td>
</tr>
<tr>
<td>Eric McClendon</td>
<td>emcclенд@wakehealth.edu</td>
<td>Mentee</td>
</tr>
<tr>
<td>Walter Beard</td>
<td><a href="mailto:wbeard@umc.edu">wbeard@umc.edu</a></td>
<td>Mentee</td>
</tr>
<tr>
<td>Kenneth Butler</td>
<td><a href="mailto:kbutler@umc.edu">kbutler@umc.edu</a></td>
<td>Co-investigator</td>
</tr>
<tr>
<td>Thomas Mosley</td>
<td><a href="mailto:tmosely@umc.edu">tmosely@umc.edu</a></td>
<td>Co-investigator</td>
</tr>
<tr>
<td>Herman Taylor</td>
<td><a href="mailto:htaylor@umc.edu">htaylor@umc.edu</a></td>
<td>Co-investigator</td>
</tr>
<tr>
<td>Scott D. Solomon</td>
<td><a href="mailto:ssolomon@partners.org">ssolomon@partners.org</a></td>
<td>Co-investigator</td>
</tr>
</tbody>
</table>

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. ___EF___ [please confirm with your initials electronically or in writing]

Ervin Fox MD, MPH, FAHA, FACC
Professor of Medicine
Director of Echocardiography and Nuclear Medicine Laboratories, Department of Medicine
University of Mississippi Medical Center
2500 North State Street
Jackson, MS 39232
601-984-5678; 601-984-5683
efox@umc.edu

Ramachandran Vasan MD, DM, FAHA, FACC (PI – Boston University)
Professor of Medicine
Chief, Section of Preventive Medicine and Epidemiology, Dept. of Medicine
73 Mt. Wayte Avenue
Framingham, MA 01702
Phone: 508 935 3450
Fax: 508 626 1262
3. Timeline:

- Analysis: July-August, 2014
- Manuscript Writing: September-October 2014
- Initial Draft: October, 2014
- Editing-Final Draft: November 2014
- Draft Submitted to P and P Committee: December, 2014
- Submission to Journal for Publication: January 2015

4. Rationale:

African Americans (AA) are at an exceptionally high risk of developing heart failure (CHF), an increased susceptibility that is multifactorial and incompletely explained by the higher prevalence of standard risk factors, i.e., hypertension (HTN), obesity and diabetes (DM). AA seem to have a higher prevalence of CHF with a normal (HFPEF) vs. a reduced ejection fraction (HFREF). However, no prior study has comprehensively evaluated the prevalence of AHA-ACC CHF stages nor how these stages in this group are related to incident cardiovascular events and death. The current application will bridge this gap using data from the ARIC Study accompanied by mentoring of minority young scientists.

5. Main Hypothesis/Study Questions:
**Specific Aim:** To describe the prevalence of AHA-ACC CHF stages in approximately 1800 AA participants who were part of Exam 3 and received echocardiogram.

**Hypothesis:** We postulate that AA will have high prevalence of CHF stages B-D, and few people will be categorized as CHF class 0. We hypothesize that advanced CHF stages, including even Stage B, is associated with greater risk of mortality on follow-up.

6. **Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).**

**Risk Factor and Echo Parameter Data from ARIC Visit 3**

Risk Factors = age, sex, diabetes, hypertension, lipid profile, fasting glucose, systolic and diastolic BP, BMI, total cholesterol, HDL, LDL, waist circumference, premenopausal status, lipid lowering meds, antihypertensive meds, hormone replacement medications, diet, urinary Na from Visit 3.

Echo parameters = LV mass, LV ejection fraction and LV fractional shortening, (also for determination of CHF stage - mitral inflow velocity E, A) from Visit 3.

Prevalent heart failure will be defined hospitalization with ICD-9 code for HF (428.x) listed at discharge between visit 1 and 3 (n=34).

**Incident Events and Death**

Adjudicated Events (CHD, ischemic stroke and CHF events) from 1993 forward

Adjudicated death

<table>
<thead>
<tr>
<th>Table. Definitions of CHF stage and Key Domains of Risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACC-AHA Stage (modified)</strong></td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>A</td>
</tr>
<tr>
<td>B</td>
</tr>
<tr>
<td>C/D</td>
</tr>
</tbody>
</table>

**Statistical Analysis:** We will estimate the proportions of AAs individuals in Exam 3 in each stage of ACC-AHA CHF as:

Cases of CHF stage at Exam 3

Population at Exam 3
The estimated prevalence of ACC-AHA CHF stages will be used in a Cox proportional hazards regression analysis to predict 20-year risk of incident CVD events and death, adjusting for age and sex at the minimum. ACC-AHA CHF Stage 0/A will be considered as a reference group.

7.a. Will the data be used for non-CVD analysis in this manuscript?  
  ___ Yes  ___ X No

  b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used?  
     ___ Yes  ___ No
     (This file ICTDER has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript?  
  ___ Yes  ___ X No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?  
  ___ Yes  ___ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at:  
   http://www.cscce.edu/ARIC/search.php

  ___ X___ Yes  ______ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

None: This proposal utilizes additional HF case ascertainment from ancillary study data collection retrospectively to visit 3 and relates stages of CHF to incident events and mortality.

11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?  
  ___ X___ Yes  ____ No

11.b. If yes, is the proposal
A. primarily the result of an ancillary study (list number)* 2012.25
Validation of Heart Failure Hospitalizations in African Americans with
Echocardiography)

B. primarily based on ARIC data with ancillary data playing a minor
role (usually control variables; list number(s))* __________ __________

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12a. Manuscript preparation is expected to be completed in one to three years. If a
manuscript is not submitted for ARIC review at the end of the 3-years from the date
of the approval, the manuscript proposal will expire.

12b. The NIH instituted a Public Access Policy in April, 2008 which ensures that the
public has access to the published results of NIH funded research. It is your
responsibility to upload manuscripts to PUBMED Central whenever the journal does
not and be in compliance with this policy. Four files about the public access policy from
shows you which journals automatically upload articles to Pubmed central.

(1) Roger VrL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB,
Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Halipern SM,
Heit JA, Howard VJ, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth
LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D,
Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorelie PD, Sotoodehnia N,
Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart Disease and Stroke

(2) Yancy CW. Heart failure in blacks: etiologic and epidemiologic differences. Curr

(3) Yancy CW, Strong M. The natural history, epidemiology, and prognosis of heart

JAC. Differences in the Incidence of Congestive Heart Failure by Ethnicity: The

(5) Bibbins-Domingo K, Fletcher MJ, Lin F, Vittinghoff E, Gardin JM, Aryanchna A,
Lewis CE, Williams OD, Hulley SB. Racial Differences in Incident Heart Failure

(6) Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity

(7) Barnes PM SC. Trends in adults receiving a recommendation for exercise or
other physical activity from a physician or other health professional. 2012.
National Center for Health Statistics, Hyattsville, MD.


